Compare Hinge Health Inc. Class A Common Stock (HNGE) vs Roundhill Magnificent Seven ETF (MAGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hinge Health Inc. Class A Common Stock vs Roundhill Magnificent Seven ETF — how do they compare? Hinge Health Inc. Class A Common Stock trades at $104.95 (market cap $8.48B), while Roundhill Magnificent Seven ETF trades at $72.19 (market cap $5.89B). The key difference: Hinge Health Inc. Class A Common Stock is the larger of the two by market cap, and Hinge Health Inc. Class A Common Stock is trading nearer its 52-week high, Roundhill Magnificent Seven ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Hinge Health Inc. Class A Common Stock for 0 Days and Roundhill Magnificent Seven ETF for 35 Days on average.
| HNGE | MAGS | |
|---|---|---|
Market Cap | $8.48B | $5.89B |
Volume | 879,799 | 3,080,349 |
Sector | Health | Sector/Thematic |
52-Week High | $105.14 | $74.30 |
52-Week Low | $31.17 | $55.39 |
Typical Hold Time | 0 Days | 35 Days |
Enterprise Value | $8.10B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hinge Health (HNGE) trades at $105.14, up 0.31% on the day and near its 52-week high. The stock shows strong analyst support with a 93.75% buy rating, though the current price exceeds the consensus target of $101.62. Recent earnings beat expectations in two of the last three quarters, with Q3 2026 results due November 2. Fundamentals indicate robust revenue growth projections from $588 million in 2025 to $720 million in 2026, alongside a shift to profitability, but valuation multiples like EV/EBITDA at 82.33 remain elevated.
The outlook is cautiously optimistic given projected profitability and expansion into migraine and GI care, but risks include high insider selling, competitive pressures, and the stock's premium valuation. Execution on growth targets and Q3 earnings will be critical for sustaining momentum.
MAGS, the Roundhill Magnificent Seven ETF, trades at $74.30, up 0.43% on the day, with a bullish technical signal driven by moving averages. The ETF provides equal-weighted exposure to seven mega-cap tech stocks, though it has underperformed the S&P 500 in 2026 with a modest 2% year-to-date gain. Recent news highlights the group's focus on AI growth but notes a potential shift in market leadership away from the concentrated 'Magnificent Seven' theme.
The outlook for MAGS hinges on the continued AI-driven performance of its holdings, but risks include high concentration, valuation concerns, and market rotation. Investor sentiment is mixed, with some analysts advocating for the basket approach while others warn of fragmentation. Upside potential exists if the mega-caps reassert dominance, but diversification pressures pose a headwind.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Hinge Health Inc. Class A Common Stock
Hinge Health Inc. operates a digital musculoskeletal (MSK) care platform that delivers exercise therapy for joint and muscle conditions through health plans and employers. Its Precision Motion Technology combines wearable sensors and computer vision to guide patients through clinician-directed physical therapy remotely.
Read more on HNGE →About Roundhill Magnificent Seven ETF
MAGS is an ETF that provides concentrated exposure to the seven technology-focused mega-cap companies often referred to as the 'Magnificent Seven' (Alphabet, Amazon, Apple, Meta, Microsoft, NVIDIA, and Tesla). The fund is designed to capture the performance of these market-leading stocks, which have been the primary drivers of market returns. It offers a simple way for investors to invest solely in this select group of high-growth technology companies.
Read more on MAGS →
